Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact ...

Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...

Complement 3 glomerulopathy (C3 glomerulopathy) is a very rare kidney disease. Those diagnosed with it have one of two forms of this disease: dense deposit disease (DDD) or C3 glomerulonephritis (C3GN ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

C3G and IC-MPGN both cause protein deposits that reduce kidney function. Overactive proteins in the immune system lead to these different conditions. C3G and IC-MPGN are rare kidney conditions. They ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication that can occur after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Study finds that despite ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the ...